ClinicalTrials.gg
CompletedNCT06648200Updated Oct 15, 2026

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

A Phase 2 interventional study of JS004 and Toripalimab in Small Cell Lung Cancer Extensive Stage and Small Cell Lung Cancer Recurrent, sponsored by Shanghai Pulmonary Hospital, Shanghai, China. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Shanghai Pulmonary Hospital, Shanghai, China · Phase 2, Interventional, and Treatment

How we know

Updated Oct 15, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Small Cell Lung Carcinoma by Shanghai Pulmonary Hospital, Shanghai, China — 9 open to participants now, 9 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Shanghai Pulmonary Hospital, Shanghai, China.

Enrollment
2nd of 13
100 · median 40
Started
2024
with 3 others
Phase 2
11 of 15
6 open now
Registered
10th of 15
by date

Among the 15 studies in Small Cell Lung Carcinoma by Shanghai Pulmonary Hospital, Shanghai, China, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 in phase 2, and was the 10th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 15 studies in Small Cell Lung Carcinoma by Shanghai Pulmonary Hospital, Shanghai, China are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Small Cell Lung Carcinoma by Shanghai Pulmonary Hospital, Shanghai, China, or all of them as a file.
02

Study summary

For extensive-stage small cell lung cancer (SCLC), platinum-chemotherapy (cisplatin or carboplatin) combined with etoposide as the first-line treatment is recommended. However, the recurrence rate is extremely high after the initial first-line treatment. For those who relapse or progress within more than six minths after the end of the-first-line treatment, chose the current guideline recommendation trearment plan has the poor prognosis. A new immunotherapeutic strategy is needed to achieve better anti-tumor effects. JS004 is a new antibody targeting B and T lymphocyte attenuator (BTLA), which restrains immune cells; function and leads to immune escape of tumor cells. The combination of PD-1 and BTLA antibodies has shown a good therapeutic effect in solid tumors. This trial aims to investigate the efficacy and safety of the therapeutic regimen of toripalimab and JS004 combined with platinum-based doublet chemotherapy in extensive-stage SCLC or relapsed within more than six months after radical treatment SCLC.

03

Conditions studied

  • Small Cell Lung Cancer Extensive Stage
  • Small Cell Lung Cancer Recurrent

Keywords

  • small cell lung cancer
  • Toripalimab
  • JS004
  • Extensive-stage
  • Recurrent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient shall sign the Form;
  2. Aged 18 ≥ years;
  3. Histological or cytological diagnosis of SCLC by needle or EBUS, and extensive stage or recurrent confirmed by imageological examinations or within more than six months after radical treatment SCLC;
  4. (ECOG) performance-status score of 0 or 1;
  5. is at least 12 weeks;
  6. At least 1 according to 1.1;
  7. Patients with good function of other main organs (liver, kidney, blood system, etc.);
  8. Fertile female patients must voluntarily use effective from the start of the trial to within 30 days after its completion, and urine or serum pregnancy test results within 7 days prior to enrollment are negative;
  9. Unsterilized male patients must voluntarily use effective contraception during the trial period and for 30 days after its conclusion.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a other than SCLC within five years prior to the start of this trial;
  2. Participants with any unstable systemic disease (including uncontrolled hypertension, severe arrhythmia, etc.);
  3. With activate or suspectable disease, or autoimmune paracancer syndrome requiring systemic treatment;
  4. Participants who are allergic to the test drug or any auxiliary materials;
  5. Participants with active , or ;
  6. Participants with Interstitial lung disease currently;
  7. Pregnant or lactating women;
  8. Any malabsorption;
  9. Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
  10. Other factors that researchers think it is not suitable for enrollment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Therapy With Toripalimab Combined With Platinum-based Doublet Chemotherapy

    In this arm, patients with extensive-stage small cell lung cancer or relapsed within more than 6 months after SCLC radical treatment will receive 4 circles of toripalimab combined with platinum-based doublet chemotherapy. Then patients received maintenance treatment with toripalimab until the disease progressed.

    Drug: Toripalimab · Drug: Etoposide · Drug: Platinum

  • Experimental
    Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy

    In this arm, patients with extensive-stage small cell lung cancer or relapsed within more than 6 months after SCLC radical treatment will receive 4 circles of toripalimab and JS004 combined with platinum-based doublet chemotherapy. Then patients received maintenance treatment with toripalimab and JS004 until the disease progressed.

    Drug: JS004 · Drug: Toripalimab · Drug: Etoposide · Drug: Platinum

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    It is defined as the time (months) from randomization to the first occurrence of disease progression according to RECIST 1.1 or death from any cause short of progression.

    Time frame: up to 60 months

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined according to the RECIST v1.1 criteria.

    Time frame: up to 30 months

  2. Treatment-related adverse event (TRAE)

    TRAE is defined and classified according to NCI-CTCAE v5.0 in all participants.

    Time frame: Up to 30 months

  3. Overall survival (OS)

    It is defined as the time (months) from randomization to the death generated by any cause.

    Time frame: up to 60 months

  4. Health related quality of life (HRQol):EORTC-QLQ-C30

    The assessment is made according to the Quality of Life Scale for Lung Cancer Patients (EORTC-QLQ-C30 , Version 3). EORTC's QLQ-C30 (V3.0) is a core scale for lung cancer patients, with a total of 43 items. Among them, Item 29 and 30 are divided into seven grades, which are assigned with 1 to 7 scores according to the answer options.

    Time frame: up to 5 months

  5. Health related quality of life (HRQol):LC13

    The assessment is made according to the Quality of Life Scale for Lung Cancer Patients (LC13, Version 3).The items are divided into 4 grades: Not at All, A Little, Quite a Bit, and Very Much, assigned with 1 to 4 scores respectively. The higher score, the worse quality.

    Time frame: up to 5 months

07

Study locations

1 site
  • Shanghai Pulmonary Hospital
    Shanghai, China 200433, China
08

References and documents

Individual participant data

Plan to share: Undecided — The researchers will consider whether IPD is available to other researchers only after the paper is published.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Aug 2026, 21 months.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's 21 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Sep 2030 → Aug 2026 and completion Sep 2030 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 18, 2024
StartActual
Nov 18, 2024
Primary completionActual
Aug 29, 2026was Sep 2030
CompletionActual
Aug 29, 2026was Sep 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 15, 2026
Sites
1 site added, 1 site removed
Show site
  • Shanghai Pulmonary Hospital · Shanghai, China
Show 1 removed
  • Shanghai Pulmonary Hospital · Shanghai, China
Oct 15, 2026
Start date
Nov 1, 2024→Nov 18, 2024 (actual)
Oct 15, 2026
Primary completion
Sep 1, 2030→Aug 29, 2026 (actual)
Oct 15, 2026
Study completion
Sep 1, 2030→Aug 29, 2026 (actual)
Oct 15, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionProgression-free survival (PFS): how it is measured was reworded
Oct 15, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionOverall survival (OS): how it is measured was reworded
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Shanghai Pulmonary Hospital · Shanghai, China
    Show 1 removed
    • Shanghai Pulmonary Hospital · Shanghai, China
    Start date Nov 1, 2024→Nov 18, 2024 (now actual)
    Primary completion Sep 1, 2030→Aug 29, 2026 (now actual)
    Study completion Sep 1, 2030→Aug 29, 2026 (now actual)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionProgression-free survival (PFS): how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionOverall survival (OS): how it is measured was reworded
    + 5 other changes: verification date, design details, arm descriptions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06648200
Responsible party
Peng Zhang (Professor, Shanghai Pulmonary Hospital, Shanghai, China) — Principal investigator
First posted
Oct 18, 2024
Start date
Nov 18, 2024
Primary completion
Aug 29, 2026
Completion
Aug 29, 2026
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tifcemalimab

Start the discussion